Bitcoin Latinum Launches To be World’s Largest Insured Cryptocurrency with Backing From Titans of Industry
Bitcoin Latinum, the next-generation Bitcoin fork capable of massive transaction volume, digital asset management, cyber security, and capacity is announcing its official pre-sale launch. Bitcoin Latinum will trade under the symbol LTNM with a total supply of 888,888,888 LTNM [verifiable by LTNM].
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005585/en/
Bitcoin Latinum (Photo: Business Wire)
Bitcoin Latinum is now available for pre-sale on bitcoinlatinum.com and will be available on exchanges in 2021.
Bitcoin Latinum is an enhanced Bitcoin fork. The Bitcoin Latinum algorithm and infrastructure break barriers and speed limits that have prevented some virtual currencies from achieving practical, real-time use. Bitcoin Latinum taps into the new wave of crypto DeFi — decentralized finance — for its role in independent digital transactions. According to Nasdaq, the total DeFi related cryptocurrency market recently passed $14 billion, up from $1 billion in February 2020.
The Bitcoin Latinum tokens are a part of a blockchain ecosystem being adopted by companies in media, gaming, storage, cloud, and telecommunications. Bitcoin Latinum tokens will be interchangeably used on each of these partner/supplier networks by consumers. In addition, Bitcoin Latinum adds security around inflight transactions and enhanced mining node protection based on memory scanning technology. Furthermore, Bitcoin Latinum looks to reduce the cost of a Bitcoin transaction from dollars to pennies for on-chain transactions and even lower rates for lightning-based transactions.
Marsh & McLennan, one of the world’s leading specialty insurance brokers and risk advisers, has been appointed to arrange a comprehensive insurance program for Bitcoin Latinum. The insurance coverage, to be arranged by Marsh Asia, will protect Bitcoin Latinum holders in case of external theft and internal collusion, potentially up to the full value of their holdings. This contemplated insurance coverage will make Bitcoin Latinum the world’s largest insured digital asset.
Draper Dragon Fund will be playing a major role with Bitcoin Latinum. Draper Dragon Fund has invested in blockchain companies Telegram, Ledger, Vechain, Ultrain, Aelf and Token Insight. “The partnership with Marsh, Monsoon, and Bitcoin Latinum would further extend our digital asset portfolio,” said Richard Wang, Managing Partner of Dragon Digital Fund. Draper Dragon is an extension of the Draper Venture Network (DVN) backed by billionaire Tim Draper who is often regarded as one of the most successful venture capitalists in the world.
Adopting Bitcoin Latinum is Academy Award winning studio Cross Creek Media. Cross Creek has grossed over $1.7 billion in the worldwide box office. Cross Creek Media, who has long term relationships with Sony Pictures Entertainment and Universal Pictures, most recently expanded its digital assets in film, television, and IP with Monsoon Blockchain & Marsh. Cross Creek has been a co-financier/producer of such films as Oscar winner Black Swan and has been behind hits American Made, Everest, and Hacksaw Ridge. Timmy Thompson, CEO of Cross Creek Media stated, “We are very excited about Bitcoin Latinum and its capabilities as an insured token, as we continue developing award-winning properties. Cross Creek's portfolio of new media technology investments perfectly positions us to take advantage of the digital asset sector in Media and Gaming.”
Bitcoin Latinum has selected Hong Kong's Hex Trust, the leading digital asset custody platform for the banking sector, to be a digital asset custodian for the new token. Built with banks and financial institutions in mind, Hex Trust offers hardware security modules from IBM, and is connected to the SWIFT payment network. Recently, Hex Trust partnered with Milan-based global leader, SIA, which processes over $14 billion in digital payments and over $16 billion in institutional services transactions each year.
The implementation of blockchain and cryptocurrencies in the banking and finance sectors has been steadily increasing in the past two years. JPMorgan Chase ($2.98 Trillion AUM) recently launched a digital currency for large technology clients, and PayPal will now allow its close to 350 million users to purchase and sell major cryptocurrencies, including Bitcoin. The blockchain network Spunta has already been adapted by many of Italy’s banks, and it is being reported that a digital version of the Yuan is being tested by the People’s Bank of China.
Bitcoin’s market cap is nearing $200 billion and makes up approximately 84% of the cryptocurrency market. Bitcoin recently skyrocketed past $18,000 per token, demonstrating a strong bull market. Earlier this year, Gartner stated that blockchain technology will create more than $176 billion worth of business value by 2025, and $3.1 trillion by 2030. There are trillions of dollars in global assets that could potentially be digitized.
The incorporation of Bitcoin and cryptocurrencies into US and Asia cross-border deal flow of digital assets has been increasing exponentially. Monsoon Blockchain, Asia’s premiere blockchain company, will be adapting Bitcoin Latinum in their extensive ecosystem and pipeline of digital asset deals. Monsoon is focused on becoming the company pioneering the adoption of highly secure decentralized asset management. Earlier this year Monsoon Blockchain formed major partnerships in the blockchain and digital asset space with governments, telecom, media and entertainment, and fintech industries.
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any Bitcoin Latinum offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. Bitcoin Latinum strongly recommends you consult a licensed or registered professional before making any investment decision.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Named Global Top Employer for Fourth Consecutive Year25.1.2021 03:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda was also certified as a Top Employer in four regions and 38 countries. This underscores the company’s commitment to creating an exceptional people experience for its global workforce. For more than 30 years, Top Employers Institute has given annual award certification to companies with outstanding culture, work environments, benefits and opportunities for their people. The Institute certifies organizations based on the results of its HR Best Practices Survey. The survey covers 20 people-centric topic areas, including Career Development, Culture, Diversity & Inclusion, Learning, Sustainability, Values, Well-being and Work Environment. “We are very proud of the global, regional and country recognition we’ve received from Top
GPD Companies, Inc. to Acquire Distrupol22.1.2021 16:33:00 EET | Press release
GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 14:50:00 EET | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Dec. 31, 2020 Sept. 30, 2020 Dec. 31, 2019 Sequential Year-on-year Revenue $5,532 $5,258 $8,228 5% -33% Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4% Net income (loss) - GAAP basis $374 $(82) $333 n/m 12% Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33% Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bps Pretax segment operating income* $654 $575 $1,006 14% -35% Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bps Net income, excluding charges & credits* $309 $228 $545 35% -43% Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26% North America 1,167 1,034 2,339 13% -50% Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)22.1.2021 09:00:00 EET | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/ Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire) Development Background Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class res
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment22.1.2021 01:12:00 EET | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine — dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV H
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)22.1.2021 00:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde
Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 19:45:00 EET | Press release
Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom